Naruhiro Kayukawa
Kyoto, 6028566, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Apalutamide versus bicalutamide in combination with androgen deprivation therapy for metastatic hormone sensitive prostate cancer.
Journal: Scientific reports
Published: October 09, 2023
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
Journal: World journal of urology
Published: August 17, 2022
MRGBP promotes AR-mediated transactivation of KLK3 and TMPRSS2 via acetylation of histone H2A.Z in prostate cancer cells.
Journal: Biochimica et biophysica acta. Gene regulatory mechanisms
Published: February 13, 2018
CNPY2 inhibits MYLIP-mediated AR protein degradation in prostate cancer cells.
Journal: Oncotarget
Published: September 29, 2017
CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
CNPY2 promoted the proliferation of renal cell carcinoma cells and increased the expression of TP53.
Journal: Biochemical and biophysical research communications
Published: February 13, 2017
Androgen suppresses testicular cancer cell growth in vitro and in vivo.
Journal: Oncotarget
Published: December 02, 2015
PAX2 promoted prostate cancer cell invasion through transcriptional regulation of HGF in an in vitro model.
Journal: Biochimica et biophysica acta
Published: May 10, 2015
A genetic screen in Drosophila for regulators of human prostate cancer progression.
Journal: Biochemical and biophysical research communications
Published: July 26, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026